Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
[dedifferentiated liposarcoma]
Liposarcomas
are
a
heterogenous
group
of
fat-derived
sarcomas
,
and
surgery
with
or
without
chemoradiation
therapy
remains
the
main
stay
of
treatment
.
NY
-ESO-
1
is
a
cancer
-testis
antigen
expressed
in
various
cancers
where
it
can
induce
both
cellular
and
humoral
immunity
.
Immunotherapy
has
shown
promise
in
clinical
trials
involving
NY
-ESO-
1
-
expressing
tumors
.
Gene
expression
studies
have
shown
upregulation
of
the
gene
for
NY
-ESO-
1
,
CTAG
1
B
,
in
myxoid
and
round
cell
liposarcomas
.
Herein
,
we
evaluated
the
expression
of
NY
-ESO-
1
among
liposarcoma
subtypes
by
quantitative
real-time
PCR
,
western
blot
analysis
,
and
immunohistochemistry
.
Frozen
tissue
for
quantitative
real-time
PCR
and
western
blot
analysis
was
obtained
for
the
following
liposarcoma
subtypes
(
n
=
15
)
:
myxoid
and
round
cell
(
n
=
8
)
;
well-differentiated
(
n
=
4
)
,
and
dedifferentiated
(
n
=
3
)
.
Formalin-fixed
paraffin-embedded
blocks
were
obtained
for
the
following
liposarcoma
subtypes
(
n
=
44
)
:
myxoid
and
round
cell
(
n
=
18
)
;
well-differentiated
(
n
=
10
)
;
dedifferentiated
(
n
=
10
)
;
and
pleomorphic
(
n
=
6
)
.
Full
sections
were
stained
with
monoclonal
antibody
NY
-ESO-
1
,
and
staining
was
assessed
for
intensity
(
1
-
3
+
)
,
percentage
of
tumor
positivity
,
and
location
.
In
all
,
7
/
8
(
88
%
)
and
16
/
18
(
89
%
)
myxoid
and
round
cell
expressed
CTAG
1
B
and
NY
-ESO-
1
by
quantitative
real-time
PCR
and
immunohistochemistry
,
respectively
.
Western
blot
correlated
with
mRNA
expression
levels
.
By
immunohistochemistry
,
94
%
(
15
/
16
)
of
positive
cases
stained
homogenously
with
2
-
3
+
intensity
.
Also
,
3
/
6
(
50
%
)
pleomorphic
liposarcomas
demonstrated
a
range
of
staining
:
1
+
intensity
in
50
%
of
cells
;
2
+
intensity
in
5
%
of
cells
;
and
3
+
intensity
in
90
%
of
cells
.
One
case
of
dedifferentiated
liposarcoma
showed
strong
,
diffuse
staining
(
3
+
intensity
in
75
%
of
cells
)
.
Our
study
shows
that
both
CTAG
1
B
mRNA
and
protein
are
overexpressed
with
high
frequency
in
myxoid
and
round
cell
liposarcoma
,
enabling
the
potential
use
of
targeted
immunotherapy
in
the
treatment
of
this
malignancy
.
Diseases
Validation
Diseases presenting
"shown promise in clinical trials"
symptom
dedifferentiated liposarcoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom
